Literature DB >> 9950798

Discrimination, adjusted correlation, and equivalence of imprecise tests: application to glucose tolerance.

J Levy1, R Morris, M Hammersley, R Turner.   

Abstract

Comparison studies between physiological tests are often unsatisfactory for assessing their ability to distinguish between subjects. We recommend a simple but comprehensive protocol, using duplicate testing, that compares tests using 1) the discriminant ratio (DR) between the underlying between- and within-subject SDs, 2) correlation coefficients adjusted for attenuation due to test imprecision, and 3) unbiased estimation of the underlying linear relationship between test results. The following five alternative methods for assessing glucose tolerance were compared: fasting plasma glucose (FPG) as a single sample or as the mean of three 5-min samples (FPG3); the 1- and 2-h glucose during a low-dose intravenous glucose infusion (CIG); and the 2-h plasma glucose from a 75-g oral glucose tolerance test (OGTT). All tests had similar DRs ranging from 2.6 to 4.2. The adjusted correlation between FPG and CIG tests approached unity, and those between OGTT and other tests were approximately 0.9, showing that FPG3 provides similar information to the OGTT. FPG concentrations of 6.0 and 7.1 were found equivalent to the 1985 World Health Organization OGTT thresholds for impaired glucose tolerance and diabetes (7.8 and 11.1 mmol/l).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950798     DOI: 10.1152/ajpendo.1999.276.2.E365

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Early Life Adversity with Height Stunting Is Associated with Cardiometabolic Risk in Adolescents Independent of Body Mass Index.

Authors:  Brie M Reid; Michelle M Harbin; Jessica L Arend; Aaron S Kelly; Donald R Dengel; Megan R Gunnar
Journal:  J Pediatr       Date:  2018-08-23       Impact factor: 4.406

2.  DISTq: An Iterative Analysis of Glucose Data for Low-Cost, Real-Time and Accurate Estimation of Insulin Sensitivity.

Authors:  Paul D Docherty; J Geoffrey Chase; Thomas Lotz; Christopher E Hann; Geoffrey M Shaw; Juliet E Berkeley; J I Mann; Kirsten McAuley
Journal:  Open Med Inform J       Date:  2009-12-02

Review 3.  Insulin resistance and the metabolic syndrome--or the pitfalls of epidemiology.

Authors:  J S Yudkin
Journal:  Diabetologia       Date:  2007-06-26       Impact factor: 10.122

4.  Use of the DISST model to estimate the HOMA and Matsuda indexes using only a basal insulin assay.

Authors:  Shaun M Davidson; Paul D Docherty; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2014-05-12

Review 5.  Integrating anthropometric and cardiometabolic health methods in stress, early experiences, and development (SEED) science.

Authors:  Jenalee R Doom; Brie M Reid; Emily Nagel; Sheila Gahagan; Ellen W Demerath; Julie C Lumeng
Journal:  Dev Psychobiol       Date:  2020-09-09       Impact factor: 3.038

6.  Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

Authors:  Michel P Hermans; Frank M Sacks; Sylvie A Ahn; Michel F Rousseau
Journal:  Cardiovasc Diabetol       Date:  2011-02-28       Impact factor: 9.951

7.  Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids.

Authors:  Michel P Hermans; Sylvie A Ahn; Michel F Rousseau
Journal:  Cardiovasc Diabetol       Date:  2014-03-10       Impact factor: 9.951

8.  Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study.

Authors:  Stephen M P O'Riordan; Peter Hindmarsh; Nathan R Hill; David R Matthews; Sherly George; Peter Greally; Gerard Canny; Dubhfeasa Slattery; Nuala Murphy; Edna Roche; Colm Costigan; Hilary Hoey
Journal:  Diabetes Care       Date:  2009-03-11       Impact factor: 19.112

9.  Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM.

Authors:  Michel P Hermans; Sylvie A Ahn; Michel F Rousseau
Journal:  Cardiovasc Diabetol       Date:  2013-02-27       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.